Gilead Sciences, Inc [GILD] stock is trading at $125.02, down -0.14%. An important factor to consider is whether the stock is rising or falling in short-term value. The GILD shares have gain 5.20% over the last week, with a monthly amount glided 6.08%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Gilead Sciences, Inc [NASDAQ: GILD] stock has seen the most recent analyst activity on November 13, 2025, when Scotiabank initiated its Sector Outperform rating and assigned the stock a price target of $140. Previously, Daiwa Securities upgraded its rating to Outperform on August 19, 2025, and kept the price target unchanged to $128. On August 08, 2025, upgrade upgraded it’s rating to Buy but maintained its price target of $127 on the stock. Needham upgraded its rating to a Buy but stick to its price target of $133 on July 25, 2025. Oppenheimer reiterated a Outperform rating for this stock on March 04, 2025, and upped its price target to $132. In a note dated February 18, 2025, Deutsche Bank upgraded an Buy rating on this stock but restated the target price of $120.
Gilead Sciences, Inc [GILD] stock has fluctuated between $86.08 and $127.68 over the past year. Currently, Wall Street analysts expect the stock to reach $127 within the next 12 months. Gilead Sciences, Inc [NASDAQ: GILD] shares were valued at $125.02 at the most recent close of the market. An investor can expect a potential return of 1.58% based on the average GILD price forecast.
Analyzing the GILD fundamentals
Gilead Sciences, Inc [NASDAQ:GILD] reported sales of 29.05B for the trailing twelve months, which represents a growth of 3.36%. Gross Profit Margin for this corporation currently stands at 0.79% with Operating Profit Margin at 0.36%, Pretax Profit Margin comes in at 0.34%, and Net Profit Margin reading is 0.28%. To continue investigating profitability, this company’s Return on Assets is posted at 0.14, Equity is 0.41 and Total Capital is 0.23. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.13.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 123.13 points at the first support level, and at 121.25 for the second support level. However, for the 1st resistance point, the stock is sitting at 126.27, and for the 2nd resistance point, it is at 127.53.
Ratios To Look Out For
For context, Gilead Sciences, Inc’s Current Ratio is 1.45. On the other hand, the Quick Ratio is 1.31, and the Cash Ratio is 0.76. Considering the valuation of this stock, the price to sales ratio is 5.34, the price to book ratio is 7.21 and price to earnings (TTM) ratio is 19.36.
Transactions by insiders
Recent insider trading involved Telman Deborah H, EVP, Corporate Affairs & GC, that happened on Nov 12 ’25 when 53646.0 shares were sold. Officer, DIANE E WILFONG completed a deal on Nov 13 ’25 to buy 3500.0 shares. Meanwhile, Officer DEBORAH TELMAN bought 55646.0 shares on Nov 12 ’25.
